Cipla Quality Chemical Industries Limited

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cipla Quality Chemical Industries Limited
Industry Pharmaceutical Industry
Founded 2005
Headquarters Luzira, Kampala, Uganda
Key people
Emmanuel Katongole
executive chairman
Nevin Bradford
executive director & cief executive officer
Services Pharmaceuticals
Total assets US$120 million (2012)
Number of employees
350 (2012)
Website Homepage

Cipla Quality Chemical Industries Limited (CIPLAQCIL), is a pharmaceutical manufacturing company in Uganda. According to a 2007 published report, it was the only company in Africa that manufactured triple-combination antiretroviral (ARV) drugs.[1]


The pharmaceutical manufacturing plant is in the southeastern neighborhood of Kampala, known as Luzira, in Nakawa Division, approximately 9 kilometres (5.6 mi), by road, southeast of the central business district.[2] The coordinates of the CIPLAQCIL pharmaceutical plant are 0° 18' 18.00"N, 32° 38' 24.00"E (Latitude:0.3050N; 32.6400E).[3]

The factory sits on 12 acres (4.9 ha) of well-mainicured lawns. The first plant was commissioned in 2007, with a capacity of 6 million tablets (pills) per day. A second plant is being planned on the premises, which will raise the manufacturing capacity to 18 million tablets (pills) daily.[4]

Quality Chemicals Limited[edit]

The company, known as Quality Chemicals Limited (QCL), was formed in 1997 by six investors:

QCL focused initially on the importation of generic drugs from India. In 2004, QCL convinced the Indian drug maker, Cipla, to go into a joint venture with QCL and set up a pharmaceutical plant in Uganda. Ground was broken in 2005 and the factory was commissioned in 2007.[5]

New manufacturing plant[edit]

In 2007, the company commissioned a new pharmaceutical manufacturing plant in Luzira, a suburb of Kampala, Uganda's capital and largest city. The factory initially was a joint venture between QCL, the government of Uganda, and the Indian pharmaceutical company Cipla. In 2009, TLG Capital invested an undisclosed amount of money in the project.[6] Later, Capitalworks Investment Partners, a private equity firm based in South Africa, also became a shareholder in the pharmaceutical plant.

Besides manufacturing the triple-combination ARVs, the new factory also manufactures the new antimalarial drug Lumartem, containing artemisinin and lumefantrin. Lumartem has less drug resistance than some of the commoner antimalarials like Chloroquine. The new plant is estimated to cost about US$38 million.[7] In February 2010, the government of Uganda divested from the new pharmaceutical plant by selling its shares "at cost" to Quality Chemical Industries Limited. The transaction was valued at approximately US$5 million.

In February 2011, the owners of the pharmaceutical factory announced an US$80 million expansion to the production line, to include increased production of antiretroviral and antimalarial medication.[8] In April 2012, British media reported that QCIL was in the process of expanding its manufacturing capacity fourfold. The factory had received a stamp of approval of its processes and products from the World Health Organization. The products will be initially marketed to the Eastern African countries of Burundi, the Democratic Republic of the Congo, Kenya, Rwanda, South Sudan, Tanzania, and Uganda.[9]

Ownership of pharmaceutical plant[edit]

As of March 2015, the shareholding in the pharmaceutical plant is as depicted in the table below:[10]

Shareholding In CIPLAQCIL Pharmaceutical Factory
Rank Name of Owner Percentage Ownership
1 Meditab Holdings Limited of Uganda 51.05
2 Quality Chemicals Limited of Uganda 22.05
3 Capitalworks Investment Partners of South Africa 14.40
4 TLG Capital of the United Kingdom 12.50
Total 100.00


The executive chairman of the board of directors of CIPLAQCIL is Emmanuel Katongole, who was formerly the managing director of QCIL. He replaced Francis Kitaka, the first person in East Africa to train as a biochemist,[citation needed] who served as chairman from 2005 until November 2013.[11] The managing director of CIPLAQCIL is Nevin Bradford.[12]

See also[edit]


  1. ^ Wendo, Charles (6 October 2007). "ARVs Production Starts Monday". New Vision. Retrieved 23 June 2014. 
  2. ^ "Map Showing Central Kampala And Luzira With Route Marker". Retrieved 17 March 2015. 
  3. ^ Google. "Location of CIPLAQCIL Pharmaceutical Factory At Google Maps". Google Maps. Retrieved 17 March 2015. 
  4. ^ Baguma, Raymond (18 May 2012). "Quality Chemicals Giving Ugandans Fighting Chance". New Vision. Retrieved 23 June 2014. 
  5. ^ Elvis Basudde, and Robert Kasozi (31 October 2007). "Kitaka, The Brain Behind Africa's First ARVs Factory". New Vision. Retrieved 23 June 2014. 
  6. ^ Investment International (9 September 2009). "Ugandan Project Attracts Investors". Retrieved 23 June 2014. 
  7. ^ Key, Data (2011). "Quality Chemical Industries, Uganda". Pharmaceutical Technology. Retrieved 23 June 2014. 
  8. ^ Gardner, Ann Marie (4 February 2011). "Teach a Man to Make Drugs: Pharmaceutical Companies Invest In African Generic Drug Plant". Good Is Magazine. Retrieved 23 June 2014. 
  9. ^ BBC (9 April 2012). "Making Drugs Into Profit In Uganda". BBC News. Retrieved 23 June 2014. 
  10. ^ CIPLAQCIL, . (23 November 2013). "CiplaQCIL Brief: Company Overview". Retrieved 17 March 2015. 
  11. ^ Monitor Reporter (18 October 2013). "Emmanuel Katongole: The Founder of Quality Chemicals". Daily Monitor (Kampala). Retrieved 17 March 2015. 
  12. ^ CIPLACQIL (30 November 2013). "Board of Directors of CIPLAQCIL". Retrieved 17 March 2015. 

External links[edit]

Coordinates: 00°18′18″N 32°38′24″E / 0.30500°N 32.64000°E / 0.30500; 32.64000